|
|
|
|
|
|
Management Team
David G. Watumull, President and CEO
More than twenty years experience as a biotechnology industry executive, analyst, and investment banker. Co-founder of Cardax Pharmaceuticals and co-inventor of Cardax technology. As CEO of Hawaii Biotech, led efforts that raised more than $25 million in equity financing and $30 million in grant funding. Started and led a West Nile virus vaccine program at Hawaii Biotech that achieved success in a human proof of concept study.
|
|
[In Memoriam]
Fredric J. Pashkow, M.D., Former Executive Vice President and Chief Medical Officer
Former Vice President U.S. Medical Affairs for the Cardiovascular-Thrombosis Therapeutic Area at Sanofi-Aventis; Responsible for medicals affairs and clinical trials for drugs with more than $5 billion in cardiovascular sales. Ten years at the Cleveland Clinic, former member of the Board of Directors at Hawaii Biotech.
|
|
Gilbert M. Rishton, Ph.D., Chief Science Officer
Former drug discovery and development leader at Amgen. Built Amgen's Small Molecule Drug Discovery Group, managed chemistry for preclinical and clinical development of Sensipar, and led medicinal chemistry for Amgen's Secretase Team. Founder and Director of the Channel Islands Alzheimer's Institute.
|
|
Timothy J. King, Ph.D., Vice President, Research
Over fifteen years of experience conducting biomedical research utilizing cell culture and genetically-engineered mouse model systems. Formerly a Staff Scientist at the Fred Hutchinson Cancer Research Center and Senior Director of Biological Research for Cardax Pharmaceuticals.
|
|
David M. Watumull, Director, Operations and Finance
Ten years experience in biotechnology with Hawaii Biotech and Cardax Pharmaceuticals. Has day-to-day responsibility for the Company’s financial and administrative operations as well as relations with partners and contractors for the production and testing of Cardax compounds. Manages the extensive and growing Cardax IP portfolio.
|
|
|
|
|
|
